Providers
Neurologist Dr. Curtis Schreiber highlights Alzheimer’s breakthroughs on global, national stages
Curtis P. Schreiber, M.D., board certified neurologist and dementia specialist with Missouri Memory Center at Citizens Memorial Hospital in Bolivar, recently shared his clinical experience using newly approved Alzheimer’s therapies in real-world practice with physicians in Australia, the Middle East and the United States.
In September, Dr. Schreiber traveled to Australia to speak with doctors about new treatments for Alzheimer’s disease. His visit followed Australia’s approval of two medications in May 2025, therapies that received full FDA approval in the United States in 2023 and 2024. The Missouri Memory Center and CMH Research Department participated in clinical trials that helped bring these treatments to patients.
Dr. Schreiber delivered lectures to physicians in Sydney, Melbourne and Brisbane, and also spoke to doctors in Adelaide via live broadcast and later in Perth as a recorded presentation. More than 200 doctors attended his presentations.
He later spoke at a symposium during the 150th Annual Meeting of the American Neurological Association in Baltimore, sharing updates on Alzheimer’s treatments and the Missouri Memory Center’s role in advancing care.
Last month, Dr. Schreiber shared his expertise as the keynote presenter in a continuing medical education webinar for more than 280 physicians in the Middle East, providing a global perspective on Alzheimer’s care and emerging treatment strategies.
“It’s truly a new era of treatment opportunities for the right patient diagnosed at the right stage of Alzheimer’s disease,” Dr. Schreiber said. “We now have fully FDA-approved treatments that can slow the progression of cognitive and functional decline that defines Alzheimer’s, and these treatments that have been pioneered at the Missouri Memory Center are not being used around the world.”
Journal Article Published
Dr. Schreiber was the first author of a scientific article, “Amyloid-related Imaging Abnormalities (ARIA) in the Context of Alzheimer’s Disease and Amyloid-targeting Therapies: An Introduction for Advance Practice Providers,” published Oct. 3, 2025, in the journal Drugs & Aging.
The article focuses on educating providers on the potential side effects of amyloid-targeting therapies, specifically donanemab (Kisunla™) and lecanemab (Leqembi®), used to treat early-stage Alzheimer’s disease. These therapies are designed to slow cognitive decline by targeting amyloid-beta plaques in the brain and the article helps educate providers on the potential side effects.
Patients at the Missouri Memory Center and CMH Research Department helped advance these treatments. The center participated in clinical trials for donanemab and provided real-world data on lecanemab, helping researchers and clinicians better understand how these treatments perform in everyday medical practice.
About Dr. Schreiber
Dr. Schreiber earned his medical degree and completed his neurology residency at Mayo Clinic in Rochester, Minnesota. He is board certified in neurology by the American Board of Psychiatry and Neurology. He has 35 years of experience and started Missouri Memory Center at CMH in 2015. Dr. Schreiber has served as principal investigator for 14 clinical trials in Alzheimer’s disease conducted at the CMH Research Department.
Missouri Memory Center, CMH Neurology and Headache Center and CMH Research Department are at 1245 N. Butterfield Road, Suite C1, in Bolivar. To schedule an appointment at Missouri Memory Center or for information about Alzheimer’s disease research studies at CMH, call 417-327-3530.
Curtis Schreiber, M.D.
Related Stories
